GCAN
The Greater Cannabis Company, Inc.0.0833
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
78.72KP/E (TTM)
-Basic EPS (TTM)
-0.60Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Greater Cannabis posted no revenue for Q3 ended September 30, 2025, with operating loss narrowing to $37,412 from $40,443 y/y while officers compensation held at $30,000. Q/q net loss improved sharply to $36,099 from $390,853 (derived), but YTD net loss widened to $669,369 from $135,693 y/y, driven by $232,220 loss on note conversions and $306,323 note default penalties—far exceeding the $129,199 operating loss. Cash dwindled to $21,355 amid $36,013 operating outflow; liabilities hit $1.13M including $260,000 related-party loans and $13,775 third-party notes. Reverse split effective October 16, 2025 reduced shares to 900,256. Funding remains elusive.
8-K
CEO secures voting control
The Greater Cannabis Company filed Articles of Amendment on October 22, 2025, creating 1,000 Series B Convertible Preferred Shares issued to CEO Aitan Zacharin for waiving $20,000 in unpaid compensation. These shares grant him 51.0% voting control. CEO locks in control. Conversion yields 100,000 common shares per preferred share, but super-voting ends on transfer or partial conversion.
8-K
1-for-1,500 reverse split
The Greater Cannabis Company executed a 1-for-1,500 reverse stock split effective October 15, 2025, slashing outstanding shares from 1,349,888,436 to ~900,256. Trading resumes post-split on October 16 under ticker GCAND for 20 days with new CUSIP 391657202. Shares freed up for potential capital raises, though no plans disclosed beyond debt conversions.
10-Q
Q2 FY2025 results
The Greater Cannabis Company posted no revenue for Q2 ended June 30, 2025, with operating expenses up 23% y/y to $48,251 (derived), mainly officers compensation and other costs, yielding an operating loss of $48,251—worse than $39,257 last year. Net loss ballooned to $390,853 from $44,917 y/y, driven by $174,300 loss on notes conversion and $167,417 note default penalties. Cash dwindled to $26,712 from $57,368 at year-end after $30,656 operating burn (six months); liabilities hit $1.1M including $260,000 related-party loans and $14,157 third-party notes. Shares outstanding soared to 1.35B via conversions. Stockholders' deficiency deepened to $1.07M. Dilution accelerates.
10-Q
Q1 FY2025 results
Greater Cannabis posted no revenue for Q1 ended March 31, 2025, with operating expenses up 12% y/y to $43,536 on steady $30,000 officer pay and minor stock-based comp. Operating loss widened to $43,536 from $38,951 y/y, but net loss hit $103,511 after $57,920 loss on note conversions—far exceeding ops due to that hit and $2,055 interest. Cash dipped q/q to $46,213 from $57,368, burning $11,155 in operations; debt eased to $371,357 including $260,000 related-party loans and $111,357 third-party notes. Shares outstanding jumped to 975M on conversions. Funding stays tight. Internal controls remain ineffective.
IPO
Website
Employees
Sector
Industry
ACB
Aurora Cannabis Inc.
5.53+0.41
CBSTF
THE CANNABIST COMPANY HOLDINGS
0.10+0.03
CGC
Canopy Growth Corporation
1.83+0.17
CURLF
Curaleaf Holdings, Inc.
4.53+0.85
GTBIF
Green Thumb Industries Inc.
9.63+1.23
IMCC
IM Cannabis Corp.
1.73+0.21
INCR
Intercure Ltd.
1.45+0.05
MAJI
Marijuana Inc.
0.05-0.02
TCNNF
Trulieve Cannabis Corporation
10.58+1.31
YCBD
cbdMD, Inc.
1.43+0.23